Alkermes Inc. said Thursday a long-acting version of its schizophrenia drug Risperdal has been approved for arm injection by U.S. health regulators.
The approval by the Food and Drug Administration means Risperdal Consta is cleared for injection in the deltoid muscle of the arm, according to the company. Previously the drug was only approved as a gluteal injection.
Risperdal is manufactured by Alkermes and marketed by Janssen Pharmaceuticals, a unit of Johnson & Johnson.
The drug will come with two separate needles for injection by the end of the year.
Shares of Alkermes Inc. fell $1.06, or 9.6 percent, to close at $10.02. J&J shares fell $4.78, or 7.7 percent, to $57.58.
The approval by the Food and Drug Administration means Risperdal Consta is cleared for injection in the deltoid muscle of the arm, according to the company. Previously the drug was only approved as a gluteal injection.
Risperdal is manufactured by Alkermes and marketed by Janssen Pharmaceuticals, a unit of Johnson & Johnson.
The drug will come with two separate needles for injection by the end of the year.
Shares of Alkermes Inc. fell $1.06, or 9.6 percent, to close at $10.02. J&J shares fell $4.78, or 7.7 percent, to $57.58.
0 comments:
Post a Comment